{"id":49124,"date":"2022-10-04T13:01:44","date_gmt":"2022-10-04T11:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/"},"modified":"2022-10-04T13:01:44","modified_gmt":"2022-10-04T11:01:44","slug":"cellarity-announces-close-of-121-million-series-c-financing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/","title":{"rendered":"Cellarity Announces Close of $121 Million Series C Financing"},"content":{"rendered":"
\n

SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity<\/a>, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity\u2019s talent base, strengthen its platform, and advance its pipeline toward the clinic.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe welcome our new investors and appreciate the continued support of our current investors,\u201d said Fabrice Chouraqui, PharmD, CEO of Cellarity and a CEO-Partner at Flagship Pioneering. \u201cBy shifting the focus from a single target to the underlying cellular dysfunction, our platform unravels the complexity of disease biology to create medicines never before possible. We have already made significant progress in confirming the unique capability of our platform with the development of compounds that have been validated in vitro and in vivo, including in higher species. With this financing, we plan to advance our pipeline and showcase the immense possibilities of our approach.\u201d\n<\/p>\n

\nTo create medicines, Cellarity looks beyond individual molecular targets and instead focuses on the whole cell. The company uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. Cellarity has developed unique capabilities to link biology and chemistry with high dimensional, transcriptomic data to design medicines against the cellular signature of the disease. The Cellarity platform provides critical insights into cellular dysfunction and reveals new biology through which we can address a range of diseases, including those which presently lack a known druggable target.\n<\/p>\n

\n\u201cCellarity is truly rewriting the rules of drug creation. Disease isn\u2019t driven by one mechanism or protein, so Cellarity has developed the ability to solve disease through the lens of the entire cell,\u201d said Stephen Berenson, Chairperson of Cellarity\u2019s Board of Directors and Managing Partner at Flagship Pioneering. \u201cSince the cell is a fuller representation of disease, the platform is uniquely designed to drive higher translatability and clinical success, creating important new medicines for internal pipeline development as well as with partners.\u201d\n<\/p>\n

\nAbout Cellarity<\/b>\n<\/p>\n

\nCellarity\u2019s mission is to fundamentally redesign the way drugs are created. By shifting the focus from a single target to understanding the whole cell, Cellarity unravels complex disease biology to create treatments never before possible. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single-cell technologies, and machine learning to unravel complex disease biology and purposefully design breakthrough medicines. As Cellarity\u2019s medicines are created against many drivers of cellular disease instead of a single target, their approach is designed to drive higher clinical translatability and success and is applicable to a vast array of disease areas. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology. For more info, visit www.cellarity.com<\/a>.\n<\/p>\n

\nAbout Flagship Pioneering<\/b>\n<\/p>\n

\nFlagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $100 billion in aggregate value. To date, Flagship has deployed over $2.9 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ: DNLI<\/a>), Evelo Biosciences (NASDAQ: EVLO<\/a>), Foghorn Therapeutics (NASDAQ: FHTX<\/a>), Moderna (NASDAQ: MRNA<\/a>), Omega Therapeutics (NASDAQ: OMGA<\/a>), Rubius Therapeutics (NASDAQ: RUBY<\/a>), Sana Biotechnology (NASDAQ: SANA<\/a>), and Seres Therapeutics (NASDAQ: MCRB<\/a>).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJessica Yingling, Ph.D., press@cellarity.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49124","6":"format-standard","7":"category-industry"},"yoast_head":"\nCellarity Announces Close of $121 Million Series C Financing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellarity Announces Close of $121 Million Series C Financing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-04T11:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cellarity Announces Close of $121 Million Series C Financing\",\"datePublished\":\"2022-10-04T11:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/\"},\"wordCount\":648,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005116\\\/en\\\/1544944\\\/21\\\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/\",\"name\":\"Cellarity Announces Close of $121 Million Series C Financing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005116\\\/en\\\/1544944\\\/21\\\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg\",\"datePublished\":\"2022-10-04T11:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005116\\\/en\\\/1544944\\\/21\\\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005116\\\/en\\\/1544944\\\/21\\\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellarity-announces-close-of-121-million-series-c-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellarity Announces Close of $121 Million Series C Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellarity Announces Close of $121 Million Series C Financing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/","og_locale":"en_US","og_type":"article","og_title":"Cellarity Announces Close of $121 Million Series C Financing - Pharma Trend","og_description":"SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-04T11:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cellarity Announces Close of $121 Million Series C Financing","datePublished":"2022-10-04T11:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/"},"wordCount":648,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/","url":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/","name":"Cellarity Announces Close of $121 Million Series C Financing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg","datePublished":"2022-10-04T11:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221004005116\/en\/1544944\/21\/Cellarity_Logo_Grey_and_red_on_transparent_high_res.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cellarity-announces-close-of-121-million-series-c-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cellarity Announces Close of $121 Million Series C Financing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49124"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49124\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}